CytoPherx Inc. raised $11.7 million for the development of a device that filters the blood of kidney-disease patients.
The Ann Arbor, Mich.-based company is creating hollow-fiber dialysis filters, which doctors use to isolate and deactivate white blood cells in a patient’s circulatory system. The company focuses on treating diseases and conditions such as renal failure and inflammation caused by cardiopulmonary bypass surgery.